Literature DB >> 11576760

Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder.

J H Meador-Woodruff1, A J Hogg, R E Smith.   

Abstract

Abnormalities of the ionotropic glutamate receptors (N-methyl-D-aspartate, alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid [AMPA], and kainate) have been reported in the brain in schizophrenia, although in complex, region-specific patterns. While limbic cortex and medial temporal lobe structures have been most often studied in psychiatric illnesses, glutamate receptors are expressed in other brain regions associated with limbic circuitry, especially the striatum. In this study, we have determined striatal ionotropic glutamate receptor expression in brains from persons with schizophrenia, bipolar disorder, major depression, and a comparison group, using samples from the Stanley Foundation Neuropathology Consortium. We have determined the expression of these receptors at multiple levels of gene expression by using both in situ hybridization and receptor autoradiography. The expression of nearly all of these molecules was not different in these psychiatric conditions. The only significant changes noted were NR2D and gluR1 transcripts, and [(3)H]AMPA binding. This is the first comprehensive study of striatal ionotropic glutamate receptor expression in schizophrenia and affective disorders, and suggests that there are minimal changes in these receptors in this region of the brain in these illnesses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576760     DOI: 10.1016/s0361-9230(01)00523-8

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  43 in total

Review 1.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

2.  Changes in AMPA subunit expression in the mouse brain after chronic treatment with the antidepressant maprotiline: a link between noradrenergic and glutamatergic function?

Authors:  Chay-Hoon Tan; Xin He; Jun Yang; Wei-Yi Ong
Journal:  Exp Brain Res       Date:  2005-11-30       Impact factor: 1.972

3.  Altered GluA1 (Gria1) Function and Accumbal Synaptic Plasticity in the ClockΔ19 Model of Bipolar Mania.

Authors:  Puja K Parekh; Darius Becker-Krail; Poornima Sundaravelu; Shinsuke Ishigaki; Haruo Okado; Gen Sobue; Yanhua Huang; Colleen A McClung
Journal:  Biol Psychiatry       Date:  2017-06-27       Impact factor: 13.382

4.  Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study.

Authors:  Lesley A McCollum; Courtney K Walker; Joy K Roche; Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2015-03-27       Impact factor: 9.306

Review 5.  The anatomy of co-morbid neuropsychiatric disorders based on cortico-limbic synaptic interactions.

Authors:  S Totterdell
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

6.  Zinc transporters protein level in postmortem brain of depressed subjects and suicide victims.

Authors:  Anna Rafalo-Ulinska; Joanna Piotrowska; Agata Kryczyk; Włodzimierz Opoka; Magdalena Sowa-Kucma; Paulina Misztak; Grazyna Rajkowska; Craig A Stockmeier; Wojciech Datka; Gabriel Nowak; Bernadeta Szewczyk
Journal:  J Psychiatr Res       Date:  2016-09-13       Impact factor: 4.791

Review 7.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

8.  Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder.

Authors:  Bhaskar Roy; Michael Dunbar; Richard C Shelton; Yogesh Dwivedi
Journal:  Neuropsychopharmacology       Date:  2016-08-31       Impact factor: 7.853

Review 9.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls.

Authors:  Sumie Leung; Rodney J Croft; Barry V O'Neill; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2007-10-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.